Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant
US11576919B2 · kind B2 · utility
1Cited by
0References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 10, 2020 |
| Grant date | Feb 14, 2023 |
| Priority date | — |
| Expiry date | Nov 10, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/138
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.